Celldex Therapeutics, Inc. (NASDAQ:CLDX) Weekly Ratings on May 17, 2018

May 17, 2018 - By Benjamin Allen

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

In total 5 analysts cover Celldex (NASDAQ:CLDX). “Buy” rating has 1, “Sell” are 0, while 4 are “Hold”. 20% are bullish. 5 are the (NASDAQ:CLDX)’s analyst reports since December 6, 2017 according to StockzIntelligence Inc. On Wednesday, December 6 WBB Securities maintained the shares of CLDX in report with “Buy” rating. On Thursday, March 8 the firm has “Market Perform” rating by Leerink Swann given. On Tuesday, April 17 Cantor Fitzgerald maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating. Cantor Fitzgerald has “Neutral” rating and $3 target. On Thursday, March 8 Jefferies maintained the shares of CLDX in report with “Hold” rating. On Monday, April 16 the rating was downgraded by Cowen & Co to “Hold”. Listed here are Celldex Therapeutics, Inc. (NASDAQ:CLDX) PTs and latest ratings.

17/04/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $9 New Target: $3 Maintain
16/04/2018 Broker: Cowen & Co Rating: Hold Downgrade
08/03/2018 Broker: Jefferies Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $4 New Target: $3 Maintain
06/12/2017 Broker: WBB Securities Rating: Buy New Target: $10.0 Maintain

CLDX reached $0.6902 during the last trading session after $0.0071 change.Celldex Therapeutics, Inc. has volume of 812,203 shares. Since May 17, 2017 CLDX has declined 30.36% and is downtrending. CLDX underperformed by 41.91% the S&P500.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics.The firm is valued at $98.97 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer.Currently it has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Another two news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were briefly posted by: Globenewswire.com on May 10, 2018 with title “Celldex Provides Corporate Update and Reports First Quarter 2018 Results”. The other Seekingalpha.com‘s article was titled “Celldex Nearly Back To Square One” and posted on April 19, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.